Compositions and methods for delivery of frozen particle adhesives

• US 9,056,047 B2
• Filed: 03/20/2009
• Issued: 06/16/2015
• Est. Priority Date: 10/31/2008
• Status: Expired due to Fees

• Current Assignee: Gearbox LLC (Intellectual Ventures LLC)
• Original Assignee: The Invention Science Fund I, L.L.C. (Intellectual Ventures LLC)
• Inventors: Boyden, Edward S., Cook, Daniel B., Hyde, Roderick A., Leuthardt, Eric C., Myhrvold, Nathan P., Sweeney, Elizabeth A., Wood, Lowell L. Jr.
• Primary Examiner(s): Hartley, Michael G
• Assistant Examiner(s): Rider, Lance W
• Application Number:
  US12/383,260
• Publication Number:
  US 20120128783A1
• Time in Patent Office: 2,279 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/10 Sulfides; Sulfoxides; Sulfones
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 41/0004 Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 49/1818 particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
• CPC Class Codes: A61K 51/12 characterised by a special physical form, e.g. emulsion, microcapsules, liposomes , characterized by a special physical form, e.g. emulsions, dispersions, microcapsules liposomes A61K51/1234
• CPC Class Codes: A61K 51/1244 microparticles or nanoparticles, e.g. polymeric nanoparticles
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61K 9/007 Pulmonary tract; Aromatherapy
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61K 9/1611 Inorganic compounds
• CPC Class Codes: A61K 9/1641 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
• CPC Class Codes: A61K 9/1664 Compounds of unknown constitution, e.g. material from plants or animals oils, fats, waxes, shellac A61K9/1617
• CPC Class Codes: A61K 9/167 : with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface with further drug-free outer coating A61K9/5073
• CPC Class Codes: A61K 9/1688 : resulting in pure drug agglomerate optionally containing up to 5% of excipient
• CPC Class Codes: A61K 9/19 : lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61P 17/00 : Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 : for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: B33Y 80/00 : Products made by additive manufacturing
• CPC Class Codes: Y10T 428/2982 : Particulate matter [e.g., sphere, flake, etc.]

Abstract

Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Claims

1. A frozen particle composition, comprising:

one or more frozen solvent particles approximately 10 micrometers or smaller in size and including at least one of acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, tetrahydrofuran, acetronitrile, n-butanol, isopropanol, n-propanol, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, tert-butyl alcohol, formic acid, hydrogen fluoride, benzene, carbon tetrachloride, acetonitrile, hexane, dichloromethane, methylene chloride, methane, toluene, chloroform, or diethyl ether; and

having at least one first compartment with at least one adhesive agent located in the at least one first compartment;

wherein the at least one adhesive agent includes one or more of acrylamide polymer or copolymer, fibrin, fibrinogen, thrombin, chitin, collagen, or glycosaminoglycan;

at least one second compartment with at least one therapeutic agent located in the at least one second compartment;

wherein the at least one therapeutic agent includes one or more of an alkylating agent, antimetabolite, anthracycline, plant alkaloid, topoisomerase inhibitor, monoclonal antibody, or tyrosine kinase inhibitor.

2. The frozen particle composition of claim 1, further including at least one of polyethylene glycol, Ringer'"'"'s solution, lactated Ringer'"'"'s solution, Hartmann'"'"'s solution, acetated Ringer'"'"'s solution, phosphate buffered solution, TRIS-buffered saline solution, Hank'"'"'s balanced salt solution, Earle'"'"'s balanced salt solution, HEPES-buffered saline, dextrose, or glucose.

3. The frozen particle composition of claim 1, wherein the at least one adhesive agent includes at least one of a monomer, prepolymer, polymer, or copolymer.

4. The frozen particle composition of claim 3, wherein the at least one adhesive agent includes at least one monomer of a self-polymerizing agent.

5. The frozen particle composition of claim 3, wherein the at least one adhesive agent includes at least one nontoxic, biocompatible, bioresorbable, or biodegradable agent.

6. The frozen particle composition of claim 3, wherein the at least one adhesive agent is configured to polymerize upon administration to at least one substrate.

7. The frozen particle composition of claim 6, wherein the at least one adhesive agent is configured to polymerize at or above the temperature of the at least one substrate.

8. The frozen particle composition of claim 1, wherein the at least one adhesive agent is configured to polymerize at or above the temperature of at least one biological tissue.

9. The frozen particle composition of claim 1, wherein the at least one adhesive agent is configured to polymerize at or above the temperature of at least one subject.

10. The frozen particle composition of claim 1, further including at least one material that modulates the rate of diffusion or degradation of the at least one adhesive agent.

11. The frozen particle composition of claim 1, wherein the at least one adhesive agent includes at least one crosslinking or derivatized agent.

12. The frozen particle composition of claim 1, further including at least one therapeutic agent including at least one cytokine.

13. The frozen particle composition of claim 1, wherein the at least one adhesive agent includes a methacrylate.

14. The frozen particle composition of claim 13, wherein the at least one adhesive agent includes at least one of poly(N,N-dimethyl-N-(ethoxycarbonylmethyl)-N-[2′

-(methacryloyloxy)ethyl]-ammonium bromide) or poly(sulfobetaine methacrylate).

15. The frozen particle composition of claim 1, formulated to be administered to at least one substrate, including one or more of a cell, tissue, organ, structure, or device.

16. The frozen particle composition of claim 1, wherein the at least one adhesive agent includes a detectable state that varies with its adhesive state.

17. The frozen particle composition of claim 1, wherein the at least one adhesive agent further includes one or more of a base component, initiator component, or activator component.

18. The frozen particle composition of claim 1, wherein the at least one adhesive agent further includes at least one curing component.

19. The frozen particle composition of claim 1, wherein the adhesive agent includes at least one dye coinitiator.

20. A method for providing at least one adhesive agent to at least one substrate, comprising:

administering at least one frozen particle composition to at least one substrate, wherein the at least one frozen particle composition includes one or more frozen solvent particles approximately 10 micrometers or smaller in size and including at least one of acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, tetrahydrofuran, acetronitrile, n butanol, isopropanol, n-propanol, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, tert-butyl alcohol, formic acid, hydrogen fluoride, benzene, carbon tetrachloride, acetonitrile, hexane, dichloromethane, methylene chloride, methane, toluene, chloroform, or diethyl ether; and

having at least one first compartment with at least one adhesive agent located in the at least one first compartment;

wherein the at least one adhesive agent includes one or more of acrylamide polymer or copolymer, fibrin, fibrinogen, thrombin, chitin, collagen, or glycosaminoglycan;

at least one second compartment with at least one therapeutic agent located in the at least one second compartment;

wherein the at least one therapeutic agent includes one or more of an alkylating agent, antimetabolite, anthracycline, plant alkaloid, topoisomerase inhibitor, monoclonal antibody, or tyrosine kinase inhibitor.

21. The method of claim 20, further including at least one of polyethylene glycol, Ringer'"'"'s solution, lactated Ringer'"'"'s solution, Hartmann'"'"'s solution, acetated Ringer'"'"'s solution, phosphate buffered solution, TRIS-buffered saline solution, Hank'"'"'s balanced salt solution, Earle'"'"'s balanced salt solution, HEPES-buffered saline, dextrose, or glucose.

22. The method of claim 20, wherein the at least one substrate includes one or more of a cell, tissue, organ, structure, or device.

23. The method of claim 22, wherein the structure includes one or more of a prosthesis, cell matrix, or tissue matrix.

24. The method of claim 22, wherein the at least one substrate includes at least one cell mass.

25. The method of claim 20, wherein the at least one substrate includes one or more wounds.

26. The method of claim 20, wherein administering at least one frozen particle composition to at least one substrate includes accelerating, propelling, or ejecting the frozen particle composition toward the at least one substrate.

27. The method of claim 20, further including varying the rate, velocity, or angle at which the at least one frozen particle composition is administered to at least one substrate.

28. The method of claim 20, wherein two or more of a plurality of frozen particle compositions include two or more adhesive agents that are configured to physically or chemically bind upon administration.

29. The method of claim 20, further including administering to the at least one substrate at least one of a nanoparticle, detection material, sensor, micro-syringe, or circuit.

30. The method of claim 20, wherein the at least one adhesive agent includes a detectable state that varies with its adhesive state.

31. The method of claim 20, wherein the at least one adhesive agent further includes one or more of a base component, initiator component, or activator component.

32. The method of claim 20, wherein the at least one adhesive agent further includes at least one curing component.

33. The method of claim 20, wherein the adhesive agent includes at least one dye coinitiator.

34. A frozen particle composition, comprising:

one or more frozen particles approximately 100 microns or smaller in size and including at least one adhesive agent including one or more of acrylamide polymer or copolymer, selectin, methacrylate, silicone, glutaraldehyde, polyethylene glycol, anti-CD64 binding domain, or polysulfide;

at least one therapeutic agent including a chemotherapy drug;

at least one abrasive including at least one of alluvium, sand, calcite, emery, diamond, novaculite, pumice, borazon, corundum, or zirconia alumina;

and at least one reinforcement agent including silica beads.